TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36030342

Group type: EXPERIMENTAL
Intervention: Melatonin dispensed to children from age 5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analgesics (including opioids, gabapentinoids, and paracetamol) dispensed to adolescents from age 15
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzodiazepines and z-hypnotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall prescription drugs
Number of subjects: 0
Study: 36030462

Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478) combined with gemcitabine/cisplatin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478) combined with gemcitabine/carboplatin
Number of subjects: 31
Study: 36030576

Group type: COMPARATOR
Intervention: Isoflurane general anesthesia (BS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Postictal generalized electroencephalographic suppression (PGES)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PGES
Number of subjects: 40

Group type: COMPARATOR
Intervention: BS
Number of subjects: 40
Study: 36030593

Group type: EXPERIMENTAL
Intervention: NightWatch intervention
Number of subjects: 41
Study: 36030666

Group type: EXPERIMENTAL
Intervention: Temperament and Character Inventory (TCI)
Number of subjects: 570
Study: 36030769

Group type: EXPERIMENTAL
Intervention: Targeting SpO2 at 90-92%
Number of subjects: 18

Group type: COMPARATOR
Intervention: Targeting SpO2 at 93-95%
Number of subjects: 18
Study: 36030795

Group type: EXPERIMENTAL
Intervention: Non-recent COVID-19 group (>180 days since positive PCR test)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control group (serologically negative individuals)
Number of subjects: 501
Study: 36031093

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX), median initial dose 9.9 mg/kg
Number of subjects: 38
Study: 36031390

Group type: EXPERIMENTAL
Intervention: Very early antiretroviral treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Routine Pneumocystis jirovecii pneumonia prophylaxis
Number of subjects: 54
Study: 36031693

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (3 courses at baseline, week 24, and week 48)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (3 courses at baseline, week 24, and week 48)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 36033243

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation for CRRT
Number of subjects: 85000

Group type: COMPARATOR
Intervention: Systemic heparin anticoagulation for CRRT
Number of subjects: 85000
Study: 36033473

Group type: EXPERIMENTAL
Intervention: Lateral pelvic lymph node dissection (LPND)
Number of subjects: 387
Study: 36034306

Group type: EXPERIMENTAL
Intervention: Cognitive treatment with Brainer and physical training with jDome
Number of subjects: 78

Group type: COMPARATOR
Intervention: Cognitive treatment with Brainer and physical training with a classic bicycle
Number of subjects: 78
Study: 36034311

Group type: EXPERIMENTAL
Intervention: Deep learning system (aEYE) for nystagmus detection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep learning system (aEYE) validated folds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep learning system (aEYE) with compressed videos
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep learning system (aEYE) with varying image resolutions
Number of subjects: 0
Study: 36034404

Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension (PH) patients
Number of subjects: 15742

Group type: COMPARATOR
Intervention: Comparator group (not PH)
Number of subjects: 15742

Group type: EXPERIMENTAL
Intervention: Pulmonary arterial hypertension (largest PH group)
Number of subjects: 15742

Group type: EXPERIMENTAL
Intervention: Group 2 PH
Number of subjects: 15742

Group type: EXPERIMENTAL
Intervention: Group 3 PH
Number of subjects: 15742

Group type: EXPERIMENTAL
Intervention: Group 4 PH
Number of subjects: 15742

Group type: EXPERIMENTAL
Intervention: Group 5 PH
Number of subjects: 15742
Study: 36034411

Group type: EXPERIMENTAL
Intervention: Early treatment (initiating bevacizumab or corticosteroids treatment within three months after RN diagnosis)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Watch-and-wait policy (no early treatment)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Early treatment
Number of subjects: 641
Study: 36034445

Group type: EXPERIMENTAL
Intervention: HbA1c variability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FPG variability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Models including FPG variability
Number of subjects: 0
Study: 36034894

Group type: EXPERIMENTAL
Intervention: Mango consumption for 8 weeks
Number of subjects: 26
Study: 36034912

Group type: EXPERIMENTAL
Intervention: Individual dietetic-nutritional education program with high prebiotic and probiotic content (dairy and fermented foods, green leafy vegetables, high-fiber fruit, whole grains, etc.)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional dietary advice from specialized mental health nurses
Number of subjects: 50
Study: 36035510

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive subjects
Number of subjects: 0
Study: 36035936

Group type: EXPERIMENTAL
Intervention: Borderline pulmonary hypertension (mPAP: 21-24 mmHg)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Non-pulmonary hypertension (mPAP ≤20 mmHg)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Rehospitalization
Number of subjects: 344
Study: 36035946

Group type: EXPERIMENTAL
Intervention: Prolonged DAPT (12-24 months)
Number of subjects: 90500

Group type: COMPARATOR
Intervention: Standard DAPT (6-12 months)
Number of subjects: 90500
Study: 36035961

Group type: EXPERIMENTAL
Intervention: Higher magnesium intake (>320 mg/day)
Number of subjects: 4365

Group type: EXPERIMENTAL
Intervention: Higher magnesium intake (>320 mg/day) in diuretic users
Number of subjects: 4365
Study: 36036238

Group type: EXPERIMENTAL
Intervention: Nurse-led allergy clinic (Phase 1)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Nurse-led allergy clinic (Phase 2)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Nurse-led allergy clinic (both phases)
Number of subjects: 466
Study: 36036294

Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 32
Study: 36036522

Group type: EXPERIMENTAL
Intervention: Extravascular ICD system
Number of subjects: 356
Study: 36036663

Group type: COMPARATOR
Intervention: Fresh solution exchange
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Reuse of original solution
Number of subjects: 791
Study: 36036733

Group type: EXPERIMENTAL
Intervention: Hair cortisol concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight changes
Number of subjects: 0
Study: 36036829

Group type: EXPERIMENTAL
Intervention: Lateral 45° head-down position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbon dioxide pneumoperitoneum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36036877

Group type: EXPERIMENTAL
Intervention: Re-stratified group (RS)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard stratified group (SS)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Re-stratified group RS4
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Re-stratified groups RS2 and RS3
Number of subjects: 87
Study: 36036971

Group type: EXPERIMENTAL
Intervention: Unfollow
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Notification Settings
Number of subjects: 598

Group type: COMPARATOR
Intervention: Snooze
Number of subjects: 598

Group type: COMPARATOR
Intervention: Off-Facebook Activity
Number of subjects: 598

Group type: COMPARATOR
Intervention: Your Time on Facebook
Number of subjects: 598

Group type: COMPARATOR
Intervention: Set Daily Reminders
Number of subjects: 598
Study: 36037056

Group type: EXPERIMENTAL
Intervention: Real-Time Continuous Glucose Monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittently Scanned Continuous Glucose Monitoring
Number of subjects: 0
Study: 36037309

Group type: EXPERIMENTAL
Intervention: T2DM-obesity
Number of subjects: 99

Group type: COMPARATOR
Intervention: obesity
Number of subjects: 99

Group type: COMPARATOR
Intervention: controls
Number of subjects: 99
Study: 36037567

Group type: EXPERIMENTAL
Intervention: Lurbinectedin 3.2 mg/m
Number of subjects: 21
Study: 36037722

Group type: EXPERIMENTAL
Intervention: Resistance training (strength or power training) for 12 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study: 36037793

Group type: EXPERIMENTAL
Intervention: Cortisol awakening response (CAR) measured in saliva samples before (pre-T1) and after (post-T1) the first TKA
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone (DHEA) secretion measured in saliva samples before (pre-T1) and after (post-T1) the first TKA
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Molar CARauc/Daucawk ratio measured in saliva samples before (pre-T1) and after (post-T1) the first TKA
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Pain ratings and the amount of opioid analgesics consumed after the first and second TKAs
Number of subjects: 69
Study: 36038116

Group type: EXPERIMENTAL
Intervention: Multitask deep learning model using FAF images
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Multitask deep learning model using OCT volumes
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Multitask deep learning model using multimodal (FAF and OCT) data
Number of subjects: 1997
Study: 36038628

Group type: EXPERIMENTAL
Intervention: Responsive deep brain stimulation (DBS) of the nucleus accumbens (NAc)
Number of subjects: 2
Study: 36038633

Group type: EXPERIMENTAL
Intervention: Spa therapy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 102
Study: 36038644

Group type: COMPARATOR
Intervention: Quantitative MRI (T1 relaxation time)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Quantitative MRI (ECV fraction)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Quantitative MRI (Fat signal fraction)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Quantitative MRI (ADC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Composite Q-MRI score
Number of subjects: 101
Study: 36038699

Group type: EXPERIMENTAL
Intervention: 1 L of 0.9% saline over 30 min on two consecutive days
Number of subjects: 14
Study: 36038713

Group type: EXPERIMENTAL
Intervention: Extubation attempt
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Extubation success prediction score
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Duration of IMV
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: In-ICU mortality
Number of subjects: 1512
Study: 36038958

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation management including exercise programs, nutritional support, dysphagia evaluation, and psychological care
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation management
Number of subjects: 37
Study: 36039153

Group type: EXPERIMENTAL
Intervention: Intravenous difelikefalin (0.5 mcg/kg for up to 64 weeks)
Number of subjects: 848

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Intravenous difelikefalin
Number of subjects: 848
Study: 36039372

Group type: EXPERIMENTAL
Intervention: Social media posts from government agency
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Social media posts from near-peer parents
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Social media posts from news media
Number of subjects: 303
Study: 36039573

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 3015
Study: 36039789

Group type: EXPERIMENTAL
Intervention: 7-day low-salt diet (3.0 g/day)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 7-day high-salt diet (18 g/day)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Longitudinal changes over 14 years
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Longitudinal follow-up over 14 years
Number of subjects: 124
Study: 36039892

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL), darunavir/ritonavir (DRV/r) and/or etravirine (ETR)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: RAL, DRV/r and/or ETR
Number of subjects: 257
Study: 36039910

Group type: EXPERIMENTAL
Intervention: TAS-117
Number of subjects: 0
Study: 36039920

Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire short form 36 (SF36) item 'seldom full of pep'
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire short form 36 (SF36) item 'seldom a lot of energy'
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire short form 36 (SF36) item 'worn out'
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire short form 36 (SF36) item 'seldom happy'
Number of subjects: 756
Study: 36040321

Group type: EXPERIMENTAL
Intervention: trifluridine/tipiracil
Number of subjects: 0
Study: 36040344

Group type: EXPERIMENTAL
Intervention: Biomarker-calibrated HEI-2010 scores
Number of subjects: 100374
Study: 36040345

Group type: EXPERIMENTAL
Intervention: Personalized grocery incentive intervention
Number of subjects: 192

Group type: COMPARATOR
Intervention: BMI <25
Number of subjects: 192

Group type: COMPARATOR
Intervention: Diet-related medical condition present
Number of subjects: 192
Study: 36040352

Group type: EXPERIMENTAL
Intervention: Acculturation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet and Physical Activity
Number of subjects: 0
Study: 36040393

Group type: EXPERIMENTAL
Intervention: Profile 1 (low resilience/low adversity-LR/LA)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Profile 2 (low resilience/high adversity-LR/HA)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Profile 3 (high resilience/low adversity-HR/LA)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Profile 4 (high resilience/high adversity-HR/HA)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: HR/LA group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: LR/HA group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: LR/LA and LR/HA groups
Number of subjects: 119
Study: 36040501

Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 217
Study: 36040670

Group type: EXPERIMENTAL
Intervention: Patient navigator support over a 6-month period
Number of subjects: 24
Study: 36040767

Group type: EXPERIMENTAL
Intervention: VoiceSense digital voice analysis tool
Number of subjects: 163

Group type: COMPARATOR
Intervention: Patient Health Questionnaire-9
Number of subjects: 163
Study: 36040801

Group type: EXPERIMENTAL
Intervention: Posttraumatic stress symptoms
Number of subjects: 236

Group type: COMPARATOR
Intervention: Trauma-exposed but asymptomatic women
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Avoidance and re-experiencing symptoms
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Hyperarousal symptoms
Number of subjects: 236
Study: 36040803

Group type: EXPERIMENTAL
Intervention: Genetically determined decrease in apoC-III
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-LOF variant participants (control group)
Number of subjects: 0
Study: 36040827

Group type: EXPERIMENTAL
Intervention: Quality improvement bundle (patient education flyer, electronic health record order sets with multimodal analgesia regimens, provider education)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Quality improvement bundle
Number of subjects: 240
Study: 36041016

Group type: EXPERIMENTAL
Intervention: Rifapentine-moxifloxacin regimen
Number of subjects: 2516

Group type: COMPARATOR
Intervention: Control (6-month regimen)
Number of subjects: 2516

Group type: EXPERIMENTAL
Intervention: Rifapentine-based regimens
Number of subjects: 2516

Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 2516
Study: 36041053

Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance Plus (GLB+) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 0
Study: 36041061

Group type: COMPARATOR
Intervention: D-mannose 2 g
Number of subjects: 719

Group type: COMPARATOR
Intervention: D-mannose with herbal supplements
Number of subjects: 719

Group type: COMPARATOR
Intervention: D-mannose 500 mg plus supplements (N-acetylcysteine and Morinda citrifolia fruit extract)
Number of subjects: 719
Study: 36041086

Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin plus pembrolizumab
Number of subjects: 45
Study: 36041227

Group type: EXPERIMENTAL
Intervention: Chemical gustometry (CG) assessment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Symptom burden assessment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Correlation of melphalan levels with dysgeusia
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral microbiota assessment
Number of subjects: 45
Study: 36041429

Group type: EXPERIMENTAL
Intervention: Gemcitabine combined with apatinib and toripalimab (GAT)
Number of subjects: 41
Study: 36041755

Group type: COMPARATOR
Intervention: Any antiarrhythmic therapies (AATs) including cardioversion, catheter ablation, and fulfilled antiarrhythmic drug (AAD) prescription.
Number of subjects: 239222

Group type: COMPARATOR
Intervention: Any MHC (including depression, bipolar disorder, anxiety disorder, schizophrenia)
Number of subjects: 239222

Group type: COMPARATOR
Intervention: AAD, cardioversion, and catheter ablation use
Number of subjects: 239222
Study: 36041756

Group type: EXPERIMENTAL
Intervention: Self-rated health (per 10-point increase)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Self-rated health
Number of subjects: 574
Study: 36041981

Group type: EXPERIMENTAL
Intervention: Tapered flow resistive loading
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pressure threshold loading
Number of subjects: 21
Study: 36042020

Group type: EXPERIMENTAL
Intervention: dreaMS app tests
Number of subjects: 31
Study: 36042076

Group type: EXPERIMENTAL
Intervention: VA primary care
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: VA mental healthcare
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: VA specialty care
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Health issues
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Mental health issues
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Military sexual trauma
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Satisfaction with VA women's healthcare
Number of subjects: 1391
Study: 36042229

Group type: EXPERIMENTAL
Intervention: AS03 adjuvanted vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no adjuvant)
Number of subjects: 0
Study: 36042429

Group type: EXPERIMENTAL
Intervention: Cycling for active transportation (≥10 min/week)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Cycling for active transportation (<10 min/week)
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Walking for active transportation (≥10 min/week)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Walking for active transportation (<10 min/week)
Number of subjects: 671
Study: 36042472

Group type: EXPERIMENTAL
Intervention: Lung cancer surgery (specific type not detailed)
Number of subjects: 620
Study: 36042515

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) measured by accelerometers over 15 days across three semesters (fall 2018, spring 2019, fall 2019)
Number of subjects: 4936

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 4936
Study: 36042527

Group type: EXPERIMENTAL
Intervention: Induced hypertension treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control treatment (not specified)
Number of subjects: 34
Study: 36042629

Group type: EXPERIMENTAL
Intervention: Clariscan (gadoterate meglumine)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Other GBCAs (Dotarem®, Gadovist®, ProHance®)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: All GBCAs
Number of subjects: 766
Study: 36043180

Group type: EXPERIMENTAL
Intervention: Regdanvimab 40 mg/kg
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1315
Study: 36043184

Group type: EXPERIMENTAL
Intervention: 30 μg of SCB-2019 + CpG + aluminium hydroxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCB-2019 formulations
Number of subjects: 0

Group type: COMPARATOR
Intervention: ChAdOx1-S
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCB-2019 or ChAdOx1-S
Number of subjects: 0
Study: 36043326

Group type: EXPERIMENTAL
Intervention: Resolute Onyx zotarolimus-eluting coronary stent
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: IVUS/OCT-guided PCI
Number of subjects: 450
Study: 36043728

Group type: EXPERIMENTAL
Intervention: French version of the Bath Ankylosing Spondylitis Functional Index (BASFI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: French version of the Bath Ankylosing Spondylitis Global score (BAS-G)
Number of subjects: 0
Study: 36044159

Group type: EXPERIMENTAL
Intervention: Ultrasound screening (US) of lower limbs 48 hours after admission and again after 5 days.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care (SOC) ultrasound examination.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ultrasound screening (US) of lower limbs.
Number of subjects: 100
Study: 36044258

Group type: EXPERIMENTAL
Intervention: Data-driven scoring model for balance rehabilitation exercises
Number of subjects: 19
Study: 36044285

Group type: EXPERIMENTAL
Intervention: Unhealthy alcohol use (AUDIT-C ≥3 for women or ≥4 for men; PEth ≥50 ng/mL)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Moderate alcohol use (AUDIT-C 1-2 for women or 1-3 for men; PEth 8 ≥ 50 ng/mL)
Number of subjects: 302

Group type: COMPARATOR
Intervention: No alcohol consumption (self-report and PEth <8 ng/mL)
Number of subjects: 302
Study: 36044385

Group type: EXPERIMENTAL
Intervention: Total metabolic tumor volume (TMTV) > 220 cm3 and performance status (PS) ≥ 2
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: TMTV/Eastern Cooperative Oncology Group-PS combination
Number of subjects: 301
Study: 36044388

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel plus pembrolizumab (200 mg every 21 days for up to 6 doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel plus pembrolizumab (given the day before tisagenlecleucel)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel plus pembrolizumab
Number of subjects: 12
Study: 36044526

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1,200 mg) plus Bevacizumab (7.5 mg/kg) administered every 3 weeks
Number of subjects: 43